Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Keryx: Positive Late-Stage Results for CKD Drug

By Drug Discovery Trends Editor | March 29, 2016

​Keryx Biopharmaceuticals announced on Tuesday that its kidney disease medication met Phase 3 study endpoints. The ferric citrate drug is intended to treat iron deficiency anemia in people with chronic kidney disease (CKD) who do not require dialysis.

These initial results are statistically significant, the company said.

Keryx’s shares were up 21 percent in pre-market trade, following this news.

In the 24-week, 234-patient study of patients with moderate to severe kidney disease, 52 percent of those who received the ferric citrate treatment saw their hemoglobin levels rise by 1 g/dl of blood. Comparatively, 19 percent in the placebo group had a 1 g/dl increase.

The ferric citrate drug (called Auryxia) is approved to lower phosphate levels in the blood of CKD patients on dialysis. But based upon these Phase 3 study results, Keryx hopes to apply for an expanded approval of the oral, iron-based treatment.

Side effects of the drug included diarrhea, constipation and nausea. Twelve patients treated with ferric citrate discontinued use because of side effects, compared to 10 patients who received placebo.

Two patients in the study died, but researchers said the deaths are not related to the treatment.

Currently, Auryxia is approved in the U.S., Japan and the European Union for patients with CKD on dialysis.

R&D 100 AWARD ENTRIES NOW OPEN:

Establish your company as a technology leader! For more than 50 years, the R&D 100 Awards have showcased new products of technological significance. You can join this exclusive community!  Learn more.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE